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Abstract
Background Response to growth hormone (GH) therapy
may vary between individual patients. Therefore the use of
GH in children should be closely monitored to avoid over,
under, or ineffective treatment regimens. The treatment
response can be evaluated using growth prediction models.
In an effort to improve the accuracy of these prediction
models, Ranke et al. (J Clin Endocrinol Metab
95(3):1229–37) proposed a novel ‘data-driven’ approach
based on a quantitative analysis of a large cohort of patients
from the Pfizer International Growth Database (KIGS)
treated with Genotropin (human growth hormone). This
model allows physicians to predict and evaluate the level of
growth response and responsiveness for their patients so
they can adapt treatment accordingly. By comparing the
actually observed and the predicted growth response the
ability of an individual to respond to GH (responsiveness)
can be estimated and further treatment can be adapted
accordingly
Objective To determine the potential population level
reduction in the amount of GH used and impact on height
outcome of using this data-driven approach to guide
treatment decisions, compared to conventional, ‘experi-
ence-based’ GH treatment in prepubertal patients with
growth hormone deficiency (GHD) or Turner syndrome
(TS).
Methods A model was developed to study the height
outcome and the total amount of GH used in the presence
or absence of data-driven treatment decisions. The pro-
portion of patients for whom height outcome could be
improved or GH use could be reduced (i.e. for low com-
pliance, high or low responder) was estimated using the
KIGS cohort. The analysis assumed that this segmentation
allows physicians to tailor dosage to the individual
patient’s needs or even to discontinue therapy when it is
not effective. The analysis used a 4-year time horizon, with
Germany as an example country, but results are extendable
to other countries. Only the total amount of GH used was
included, and effects were defined as the height outcome
after 4 years.
Results The analysis estimated that an evidence-driven
approach may reduce the total amount of GH utilized by
7.0 % over 4 years for the treatment of short stature in
prepubertal patients with GHD and TS in Germany.
Despite the reduction in drug use the average growth out-
comes remained unaffected with the new treatment
approach. Univariate and probabilistic sensitivity analyses
showed that the results are robust.
Conclusions Our analysis showed that using a data-dri-
ven approach to guide treatment decisions for children with
GHD or TS is estimated to result in efficiencies in the
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amount of GH used, without reducing the average growth
in the population.
Key Points for Decision Makers
The objective of this research was to quantify the
economic value of using a new data-driven treatment
approach to optimize growth hormone treatment.
• By leveraging the real-world data from the KIGS reg-
istry, clinicians can identify those patients for whom
the growth hormone treatment may need to be tailored.
•Budget holders can realize cost efficiencies with the new
approach through appropriate management of patients
who are (1) less susceptible to treatment or, (2) who have
a low compliance to the prescribed regimen or, (3) who
are more susceptible to treatment or overtreated.
• This reduction can result in 7 % savings for total growth
hormone budget based on a simulation in Germany.
1 Introduction
Children are the main recipients of growth hormone (GH)
for the treatment of short stature in patients who have
conditions which include growth hormone deficiency
(GHD), Turner syndrome (TS), or short children born small
for gestational age (SGA). Current dosing and treatment for
GH is determined mainly on the basis of indication, height,
and weight of a patient. However, the response to therapy is
highly variable between individual patients [1] and there-
fore the use of GH in children should be closely monitored
to avoid over, under, or ineffective treatment regimens.
Although there is no harmonized standard for measuring
therapeutic response, physicians generally use two meth-
ods: (1) response criteria or cut-off values determined by
auxology or clinical outcomes [2, 3] or (2) prediction
models based on large data sets from patient registries [1,
4]. However, there are limitations with the two methods
because (1) response criteria vary between medical com-
munities and (2) the accuracy of prediction equations vary
between models [1]. There is currently also no consensus
among paediatric endocrinologists on the standard for
determining responsiveness and predicting growth [1]. In
principle though, both methods can be combined to guide
treatment decisions, and they may also be employed to
develop a personalized approach to treatment via evidence
from data on other patients treated with GH [5].
In an effort to improve upon the accuracy of prediction
models to help guide GH treatment, Ranke et al. [4] pro-
posed a novel ‘data-driven’ approach based on quantitative
analysis of a large cohort of patients in the KIGS database
(Pfizer International Growth Database, Pfizer Health AB,
Strangnas, Sweden). KIGS is a worldwide pharmaco-epi-
demiologic registry established in 1987 to monitor out-
comes and safety of Genotropin (somatropin, Pfizer Inc,
New York, NY, USA) treatment in children with short
stature. The KIGS database contains data on about 83,000
patients collected over the last 25 years in more than 50
countries. Ranke’s [4] approach is based on algorithms that
take into account both the actual (response) and predicted
(responsiveness) growth of an individual patient to deter-
mine how treatment can be optimized by the physician.
More specifically, these algorithms allow one to identify
patients who are
• Less susceptible to treatment or
• Who have a low compliance to the prescribed regimen
or
• Who are more susceptible to treatment or overtreated
Adapting treatment regimes in these patients could
potentially lead to improved height outcome (by increasing
compliance) and a reduction in the overall amount of GH
used (by altering GH dosage in patients with a high or a
low response).
The objective of this study was to determine the
potential population level reduction in GH use and impact
on height outcome of using a data-driven approach to guide
treatment decisions, compared to conventional, ‘experience
based’ GH treatment in prepubertal patients with GHD or
TS.
2 Methods
A model was developed to study the height outcome and
GH use in the presence or absence of data-driven treatment
decisions. The proportion of patients for whom height
outcome could be improved or GH use could be reduced or
discontinued (i.e. in the cases of low compliance, high or
low responder) was estimated using the KIGS cohort.
Using information from this cohort analysis, the model
estimated the impact of data-driven treatment decisions on
the amount of GH used and growth over a 4-year time
horizon. Germany was used as an example country as it
represents the largest European KIGS population (about
20 % of the European data in KIGS are from German
sites), and outcomes were presented as the number of
milligrams of GH used, to maintain transferability to other
countries. The analysis was limited to GHD and TS
because only for these indications were 4-year prediction
models for height and weight available and validated at the
time of the analysis [6].
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2.1 Response and Responsiveness
The concept published by Ranke et al. [4] uses response
and responsiveness to GH treatment to identify patient
segments based on their treatment outcomes at 12 months.
Conventionally, measures of a patient’s response com-
pared to that of a reference population have been used to
guide treatment decisions. In our study, response was
defined as the height velocity standard deviation score
(SDS): the individual’s height velocity (HV, growth in
centimetres per year) in the first year compared to that of
the reference population (age and diagnosis matched),
divided by the SD of the HV in the reference population.
Response ¼ observed HV  reference population HV
SD of HV in reference population
In line with published literature, a response lower than
-1 was considered an inadequate response [4, 7]. A
response larger than ?1, on the other hand, was considered
‘‘high’’.
Although response identifies whether a patient’s HV is
below or above the average, it does not take into account
the individual characteristics of a patient nor does it
explain why the response deviates. The index of respon-
siveness (IoR), however, compares the patients’ HV with
the individually predicted HV using published growth
prediction algorithms [8, 9]. These prediction algorithms
include many important baseline parameters such as indi-
cation, age, weight, and GH dose (Appendix 1). The IoR is
defined as
IoR ¼ observed HV  predicted HV
SD of predicted HV
An IoR lower than -1.28 or higher than ?1.28
(corresponding to the 10th and 90th centile) was
considered outside the normal range [4]. In patients with
a low IoR there should be suspicion of non-compliance or
of the effect of an unknown variable that is absent from the
prediction algorithms [4]. If, on the other hand, both the
response and IoR are high, this is most likely due to
patients being genetically more responsive to GH (i.e.
patients are high responders). However, the possibility of
patients taking a dose of GH higher than the prescribed
dose should also be considered.
By combining the response and the responsiveness, four
patient segments were defined (Fig. 1). Patients with a
response lower than the reference population were strati-
fied according to their IoR into suspected non-compliant
patients (response less than 1, responsiveness less than
-1.28) and low responders (response less than 1, respon-
siveness from -1.28 to ?1.28). It should be noted that
there may be some overlap between the suspected non-
compliance and low response groups defined here. Average
responders were those with a similar response to the ref-
erence population (response from -1 to ?1) and high
responders are those with a response higher than the ref-
erence population, and a responsiveness that is similar to or
higher than predicted (response greater than 1, respon-
siveness greater than -1.28). Inconsistent response groups
(i.e. response greater than 1 and responsiveness less than
-1.28, or response less than -1 and responsiveness greater
than 1.28) were not considered, as they are unrealistic
because of the high degree of correlation between response
and responsiveness.
To provide truly accurate growth projections, a predic-
tion system must take all possible sources of variation into
account. As the prediction algorithms explain between 29
and 70 % of the growth response during GH therapy
(30–70 % for GHD, 29–46 % for TS) [8, 9], they should be
used in conjunction with the physician’s clinical knowl-
edge and judgement.
2.2 Patient Population and Segmentation
In the base case analysis all prepubertal patients with GHD
or TS with sufficient data to assess their actual and pre-
dicted first-year response to GH treatment from the KIGS
database were included in the patient segmentation. This
includes 3,276 GHD and 2,535 TS patients from 30
European countries. For a sensitivity analysis only data
from patients in Germany was included (GHD, n = 989;
TS, n = 696). The response and responsiveness criteria
were applied to each patient, and for each segment the
mean dose, and observed and predicted HV was calculated.
Figure 2 shows that the relative size of the patient
segments in the German cohort was comparable to that in
the whole European cohort for the two indications. For
GHD patients, the average GH dose was similar in each
Fig. 1 Patient segmentation based on response and index of
responsiveness
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response group. For TS patients the average dose was
lower in the non-responder group, and similar in the other
segments. All observed average doses were within the
maximum dosing ranges stated in the Summary of Product
Characteristics (SPC) [10]. The dosing ranges for GHD are
0.025–0.035 mg/kg body weight/day, and for TS the dos-
ing ranges are 0.045–0.050 mg/kg body weight/day.
2.3 Health Resource Implication Model
A health resource implication model was developed to
predict the growth outcome and GH use for a cohort of
GHD and TS patients. The cohort size is based on all active
German patients currently in the KIGS database: 1,934
GHD patients and 326 TS patients, including those without
sufficient data for segmentation (this compares to the initial
German population used for segmentation described in
Sect. 2.2 which included both active and inactive patients
with sufficient data to assess their actual and predicted first-
year response to GH treatment from the KIGS database).
The baseline characteristics and average GH dose are also
based on the German KIGS population (Table 1). As this
model is only based on patients registered in the KIGS data-
base, all patients are considered to be treated on Genotropin.
Using a decision tree structure, we divided the cohort into
response segments as specified above. The growth and dose
for average responders were estimated using published growth
and weight prediction algorithms in GHD and TS [6, 8, 9]. The
growth and dose for high responders, non-responders and non-
compliant patients were estimated using the predicted out-
comes for average responders and the HV and dose in the
patient segments (Fig. 2), and are further described in
‘‘Appendix 2’’. To calculate the total amount of GH we
assumed that the dose is only increased once per year on the
basis of a patient’s gain in weight, as is common practice.
The time horizon of the model is limited to 4 years
because the prediction equations for height and weight have
only been validated over that time period [6, 11]. Response
to GH is strongest in the first years after treatment initiation,
and these 4 years therefore represent the most effective
period of GH therapy [8, 12].
Fig. 2 First-year outcomes for each patient segment in the KIGS database. High high response, Avg average response, NC suspected non-
compliance, LR low response, HV height velocity in the first year of treatment
Table 1 Input values used for the model which apply to the German
situation
Input
Patients in KIGS database
Paediatric GH deficiency 1,934 KIGS patients
Turner syndrome 326 KIGS patients
Patient characteristics at start of treatment
Mean age 7.99 years
Mean height 109 cm -2.91 SDS
Mean body mass index 14.8 kg/m2 -0.50 SDS
Mean parental height 166 cm -0.46 SDS
KIGS Pfizer International Growth Database, SDS standard deviation
score
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2.4 Impact of Data-Driven Treatment Decisions
in the Model
In a data-driven approach, we assumed that in high
responders the GH dose may be reduced, while still
maintaining their growth target [4]. The average HV
(annual growth) in high responders is 3 (GHD) and 2.5
(TS) cm/year above that in average responders (Fig. 2,
column 1 and 5). Both groups were treated on a similar
dose and have a similar predicted HV which suggests that
high responders are more sensitive to GH therapy. A pos-
sible mechanism for dose reduction is to maintain the
absolute dose (milligrams) in the second year of treatment,
thereby lowering the relative dose (milligrams per kilo-
gram) because patients will have gained weight during
their first year of treatment. In this scenario, we assumed
that high responders still achieve their predicted height
while reducing GH use.
For patients that are suspected to be non-compliant with
their prescribed GH regimen this analysis demonstrated
that their actual growth is 3.3 cm/year (in GHD) and
2.5 cm/year (in TS) less than predicted (Fig. 2, column 3
and 7). By identifying these low compliant cases, treating
physicians can try to find the cause of low compliance and
subsequently act on these findings at their own discretion
with the goal of improving HV for these patients. For the
analysis presented here, the model assumes, on the basis of
recommendation from experienced endocrinologists, that
compliance can be improved in around 75 % of these
patients, and that long-term non-compliant patients may
need to discontinue therapy [13, 14]. In the model, patients
with improved compliance are assumed to reach the same
height as average responders (Table 2).
For low response patients with GHD, the average HV
(growth) is 2.5 cm/year less than that of average response
patients, although both patient segments are treated on a
similar dose. This suggests that low response patients may
be less sensitive to GH therapy (Fig. 2, column 4). Among
these patients, a large proportion will never benefit from
treatment.
The situation is slightly different in the case of TS: the
low response group had an average HV (growth) of 2.2 cm/
year less than that of average response patients. However
the average dose in the low response groups was also
considerably less than the dose used to treat the patients
with an average response (0.220 vs 0.330 mg/kg/week or
0.031 vs. 0.047 mg/kg/day, Fig. 2, column 6 and 8). It is
therefore possible that the HV could be improved in a
number of these low response patients if they were to be
treated on a higher, but still appropriate, dose.
In the case of GHD low response patients and in a
fraction of TS low response patients, cessation of therapy
should be considered when all other inhibiting factors are
ruled out. This is in line with international guidelines [2,
15, 16]. Through identification of these cases after the first
year of treatment, 100 % of the GH use in these patients
may be saved in subsequent years. On the basis of rec-
ommendation from endocrinologists, the model assumes
that 80 % of low response patients would stop therapy after
the first year of treatment (Table 2). As these patients did
not show a response to GH in the first year, it is assumed
that discontinuation will not affect their growth [17].
2.5 Sensitivity Analysis
A probabilistic sensitivity analysis (PSA) was performed
on the European patient segmentation using 1,000 Monte
Carlo simulations to incorporate uncertainty in the indi-
vidual model parameters. A univariate sensitivity analysis
was performed by varying each parameter over its lower
and upper 95 % confidence interval (CI). For expert inputs,
a standard deviation of 20 % of the mean was assumed.
Table 2 Interventions by patient segment and their impact on GH use and height outcomes
Subgroup Intervention Impact on GH use Impact on height
High
response
Not increasing absolute dose after first
year, thereby lowering relative dose
due to an increase in patient’s weight
Relative dose is decreased Reduced: patients only reach their
predicted height, which is close




Continue with conventional treatment Maintain relative dose (mg/kg) Maintain average height outcome
Low
response
Discontinue therapy after the first year
for 80 % of the patients who are not
responding to therapy
100 % of GH use is saved for years 2–4 for





Improve compliance for *75 % of
patients, and discontinuing therapy for
the remainder of patients who cannot
comply
No GH use for the *25 % who discontinue
after the first year. Patients with improved
compliance have the same GH use as average
responders
Improved for *75 %. Patients
with improved compliance are
assumed to reach average height
outcome
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3 Results
3.1 Amount of GH Therapy Used and Height Gained
The predicted total amount of GH used over a 4-year time
period for all diagnosed prepubertal paediatric GHD
patients (n = 1,934) and TS patients (n = 326) in Ger-
many is 2.229 million mg without data-driven treatment
decisions and 2.072 million mg with data-driven decisions
(Table 3). The estimated reduction is thus 7.0 % of the
total amount of GH used (157,006 mg). Assuming a vial
size of 12 mg, this would correspond to an estimated
reduction of 13,084 vials of GH (an average of 5.8 vials per
patient). Table 3 shows that the estimated reduction in GH
use for GHD patients is 7.1 % (129,795 mg) and for TS
patients 6.8 % (27,210 mg). In addition, this table shows
that results were equivalent whether the EU or German
patient segments were used.
The predicted average height outcome in the total pop-
ulation without and with data-driven decisions was similar:
136.5 and 136.4 cm (difference of 0.05 cm, Table 3).
Although the height outcome for high responders was
slightly reduced because of the decreased dose, this is
compensated by the improved height outcome for low
compliant patients.
3.2 Sensitivity Analysis
The PSA scatterplot in Fig. 3 shows that the predicted
effects on height outcome range from 0.6 cm reduction
to 0.3 cm additional growth (95 % CI -0.32;
0.17 cm). The predicted reduction in GH use range
between 70,000 and 250,000 mg (95 % CI 106,481;
210,591 mg). All replications showed a reduction in
the amount of GH used for using data-driven treatment
decisions, while maintaining similar average height
outcomes.
The univariate analysis presented in Fig. 4 shows that
the future compliance (with data-driven treatment deci-
sions) is the most influential parameter on both GH use and
Table 3 GH use and height achieved for patients with growth hormone deficiency (GHD, n = 1,934) and Turner syndrome (TS, n = 326)
using the European or German patient segmentation
Indication Conventional treatment Data-driven treatment approach Efficiencies gained
GH use (million mg) Height (cm) GH use (million mg) Height (cm) Total (million mg) Per patient (mg)
European patient segmentationa
GH deficiency 1.827 137.2 1.698 137.1 0.130 67
Turner syndrome 0.402 132.1 0.375 132.2 0.027 83
Total 2.229 136.5 2.072 136.4 0.157 69
German patient segmentationb
GH deficiency 1.828 136.9 1.715 136.9 0.113 58
Turner syndrome 0.400 132.2 0.378 132.2 0.021 65
Total 2.228 136.2 2.093 136.2 0.135 59
a Segmentation based on EU KIGS population (3,276 GHD ? 2,535 TS)
b Segmentation based on German KIGS population (989 GHD ? 696 TS); see text for details
Fig. 3 Probabilistic sensitivity
analysis: scatterplot of
difference in GH use and height
outcome after 4 years of
treatment with a data-driven
approach
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effects. Higher compliance would result in more growth,
but also increases the amount of drug used, as more
patients continue treatment. To further explore the impact
of this parameter, an analysis was run in which compliance
is improved in 0 or 100 % of non-compliant patients. When
compliance cannot be improved in any of the non-com-
pliant patients, the predicted reduction in GH use according
to a data-driven approach would be 282,474 mg (as com-
pared to 157,006 mg in the base case), and the average
height outcome would decrease by 0.6 cm. When compli-
ance could be improved in all non-compliant patients, the
predicted reduction in GH use would be 111,908 mg with
an increased average height outcome of 0.2 cm.
4 Discussion
In this paper we demonstrated the potential population
level reduction in the total amount of GH used and impact
on growth when data sets like KIGS are used to help
determine whether patients are responding properly to GH
therapy. This model is unique compared to previous
models as it is possible to estimate the benefits of tailoring
GH therapy to the treatment response in individual patients,
rather than comparing standard GH regimens.
The model presented here estimates that when a data-
driven treatment approach is used in German patients
treated with Genotropin, the GH use can potentially be
reduced by 7.0 % (157,006 mg) over a 4-year period.
Through probabilistic and univariate sensitivity analyses
we were able to show that these results are robust.
Moreover we showed that the relative reduction is equiv-
alent for German or European patient segments. The pro-
portional amount of saving presented here for Germany is
therefore likely to be achievable in other European
countries.
Compared to other studies on cost-effectiveness of GH
treatment in children [18, 19], the mean age at the start of
treatment is slightly lower in our model, because a minimal
treatment period of 4 years was a prerequisite. However,
current recommendations suggest that treatment should
begin before 8 years of age (which is more in alignment
with our model), in order to achieve greater height gain
[18]. Mean height SDS at the start of therapy varies by
indication and in our model was -2.91, which is within the
range that is observed by other authors [18, 19].
It is important to consider that, although the model
seeks to differentiate between suspected non-compliant
and low-responding patients, there may be an overlap
between both groups, because they often cannot be dis-
tinguished on the basis of auxological response criteria
alone. From a clinical perspective more information in
addition to the KIGS data must be considered before
making decisions on individual treatment regimes.
However, the KIGS data can help identify patients that
potentially have a low compliance. In the analysis pre-
sented here we have accounted for this uncertainty in the
sensitivity analysis.
The low-response rate in our model is lower than that
reported by others [20]. This may be due to selection bias
by including only patients with complete follow-up over
4 years, and may also be due to the definition of low
Fig. 4 Tornado diagram of eight most influential parameters on incremental GH use and effects
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response, which was based on 80 % confidence limits.
Also, the rate of non-compliance of 8.5–10 % in our model
is more conservative than the rates of more than 30 %
found in two other studies [21, 22].
A modelling study such as this is limited by the quality
of the data and the inputs that were selected. For the GH
use and height outcome associated with each subgroup in
our study, we took population averages to calculate overall
outcomes, rather than predicting outcomes for individual
patients using discrete event simulations. Therefore, the
average cohort outcomes may not represent those of the
individual patients. In addition, the resource use only
includes the amount of drug used, and does not include
other resources such as doctor visits, devices, etc. This
indicates that the variability in resource use between
patients may be underestimated, and that the estimated
efficiencies are probably conservative.
Our analysis compared conventional, ‘experience-
based’ GH treatment with data-driven treatment decisions.
Although this could be considered overoptimistic, as phy-
sicians could also individualise treatment without data, no
studies could be identified that describe in what proportion
of patients the treatment would be adjusted. However, the
sensitivity analyses show that data-driven treatment deci-
sions are likely to result in a reduction in the amount of GH
used.
To ensure the quality of the data, only the population in
the KIGS database that had sufficient data were analysed.
This may have introduced a bias towards patients that were
monitored more closely and may be performing better than
the average population (e.g. less low-responders and non-
compliant patients). However, this would indicate that
more efficiencies can be gained in real-world practice.
5 Conclusion
If prediction algorithms are used in combination with a
data-driven approach in children receiving GH treatment,
usage of GH can be more efficient by lowering the total
dose of GH in some patients and by improving growth
outcomes in others. In conclusion, our analysis showed
that using a data-driven approach to guide treatment
decisions for children with GHD or TS is estimated to
result in substantial efficiencies in the amount of GH used
while the average growth in the population remains
unaffected.
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Appendix 2
See Tables 5, 6, and 7.
Table 5 Input parameters
Input parameter Value Source PSA value Univariate value
GHD—mean Genotropin dose 29.1 lg/kg body
weight/day
KIGS Varied over a
normal distribution
95 % CI low and high
TS—mean Genotropin dose 38.4 lg/kg body
weight/day
KIGS Varied over a
normal distribution
95 % CI low and high
Patient characteristics
Mean age 7.99 KIGS Varied over a
normal distribution
95 % CI low and high
Mean height -2.91 SDS KIGS Varied over a
normal distribution
95 % CI low and high
Mean body mass index -0.5 SDS KIGS Varied over a
normal distribution
95 % CI low and high
Mean parental height -0.46 SDS KIGS Varied over a
normal distribution
95 % CI low and high
Proportion of GHD patients male 68 % KIGS Beta distribution 95 % CI low and high
Proportion non-responders
discontinuing with services
80 % Assumption Beta distribution:
mean, 80 %; SD,
16 %
95 % CI low and high
Proportion of non-compliant
patients in which compliance can be improved
74 % Assumption Beta distribution:
mean, 74 %; SD,
15 %
95 % CI low and high
Input parameter GHD TS Source PSA value Univariate value
Proportions in each patient segment
High responders 0.132 0.142 KIGS Sampled using
a Dirichlet distribution
The proportion with a (high or normal)
response was varied to its 95 % CI, and the
proportion compliant (i.e. not non-compliant)
was varied to its 95 % CI. Other segments
were re-distributed proportionally
Average responders 0.741 0.721 KIGS
Suspected non-compliant 0.093 0.101 KIGS
Low responder 0.034 0.036 KIGS
CI confidence interval











137.2 136.4 Calculated height over 4 years using the growth
and weight gain prediction algorithms [6, 8]
Individual model parameters were
varied over their distributions using






147.1 145.9 Baseline height plus standard growth (over
4 years) multiplied by the ratio of high and
standard responders HV
The observed/predicted HV was varied







142.2 141.2 Baseline height plus observed first-year high
responder growth plus the predicted growth
for standard responders in year 2–4 multiplied
by the ratio of predicted high responder and
observed standard responders HV
±1











128.7 128.1 Baseline height plus standard growth (over
4 years) multiplied by the ratio of non-




129.2 128.5 Baseline height plus standard growth (over
4 years) multiplied by the ratio of non-






– 132.0 Calculated height over 4 years using the growth
and weight gain prediction algorithms [6, 9]
Individual model parameters were
varied over their distributions using






– 139.4 Baseline height plus standard growth (over
4 years) multiplied by the ratio of high and
standard responders HV
The observed/predicted HV was varied






– 136.1 Baseline height plus observed first year high
responder growth plus the predicted growth
for standard responders in year 2–4 multiplied
by the ratio of predicted high responder and





– 125.2 Baseline height plus standard growth (over
4 years) multiplied by the ratio of non-




– 125.5 Baseline height plus standard growth (over
4 years) multiplied by the ratio of non-
sensitive and low responders HV
±1
Baseline height height at the start of the treatment period, standard growth growth for standard responders over 4 years, as calculated using the
Ranke prediction algorithms, HV height velocity after the first year of GH therapy in cm, as observed in the KIGS patient segmentation, predicted
high responder height velocity height velocity for high responders calculated after 1 year using the growth prediction algorithms
Table 7 Dose
Patient segment Total dose
over 4 years
(mg)






901 901 Calculated using the growth and weight gain
prediction algorithms [6, 8] and the average
dose for German GHD patients in KIGS
(29.1 lg/kg body weight/day)
Individual model parameters were
varied over their distributions using





899 899 Standard dose (in mg/4 years) multiplied by
the ratio of high responder and normal
responder dose in KIGS
The observed doses from KIGS were




697 697 Calculated: assumed intervention: no dose
increase after year 1. Absolute dose remains
equal in years 2–4
Individual model parameters were
varied over their distributions using






903 903 Standard dose (in mg/4 years) multiplied by
the ratio of non-compliant and normal
responder dose in KIGS
The observed doses from KIGS were
varied over normal distributions
±5
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